Rituximab combination beneficial in aggressive non-Hodgkin’s lymphoma, say researchers
Adding rituximab (Mabthera) to standard combination chemotherapy for aggressive non-Hodgkin?s lymphoma (NHL) can prolong overall survival, according to the results of a recent trial. …
Published: 23 December 2000